Cargando…

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection

BACKGROUND: Recent studies proposed the whole-blood based IFN-γ-release assay to study the antigen-specific SARS-CoV-2 response. Since the early prediction of disease progression could help to assess the optimal treatment strategies, an integrated knowledge of T-cell and antibody response lays the f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petruccioli, Elisa, Najafi Fard, Saeid, Navarra, Assunta, Petrone, Linda, Vanini, Valentina, Cuzzi, Gilda, Gualano, Gina, Pierelli, Luca, Bertoletti, Antonio, Nicastri, Emanuele, Palmieri, Fabrizio, Ippolito, Giuseppe, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235902/ https://www.ncbi.nlm.nih.gov/pubmed/34174875 http://dx.doi.org/10.1186/s12967-021-02938-8

Ejemplares similares

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection
por: Najafi-Fard, Saeid, et al.
Publicado: (2023)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Effect of therapy on Quantiferon-Plus response in patients with active and latent tuberculosis infection
por: Petruccioli, Elisa, et al.
Publicado: (2018)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses
por: Najafi Fard, Saeid, et al.
Publicado: (2021)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Higher Frequency of T-Cell Response to M. tuberculosis Latency Antigen Rv2628 at the Site of Active Tuberculosis Disease than in Peripheral Blood
por: Chiacchio, Teresa, et al.
Publicado: (2011)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

Putting in harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for multidrug-resistant Tuberculosis. Experience from a tertiary hospital in Italy
por: Gualano, Gina, et al.
Publicado: (2019)

Concurrent cavitary pulmonary tuberculosis and COVID-19 pneumonia with in vitro immune cell anergy
por: Musso, Maria, et al.
Publicado: (2021)

Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Initial immune response after exposure to Mycobacterium tuberculosis or to SARS-COV-2: similarities and differences
por: Aiello, Alessandra, et al.
Publicado: (2023)

Optimization of the autophagy measurement in a human cell line and primary cells by flow cytometry
por: Alonzi, Tonino, et al.
Publicado: (2019)

Polyfunctional Specific Response to Echinococcus Granulosus Associates to the Biological Activity of the Cysts
por: Petrone, Linda, et al.
Publicado: (2015)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

IP-10 detection in urine is associated with lung diseases
por: Cannas, Angela, et al.
Publicado: (2010)

Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection
por: Chiacchio, Teresa, et al.
Publicado: (2017)

Quantitative and qualitative profiles of circulating monocytes may help identifying tuberculosis infection and disease stages
por: La Manna, Marco Pio, et al.
Publicado: (2017)

The best of respiratory infections from the 2015 European Respiratory Society International Congress
por: Polverino, Eva, et al.
Publicado: (2016)

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Down Syndrome patients with COVID-19 pneumonia: A high-risk category for unfavourable outcome
por: Vita, Serena, et al.
Publicado: (2021)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023)

Accuracy of an experimental whole-blood test for detecting reactivation of echinococcal cysts
por: Petrone, Linda, et al.
Publicado: (2021)

Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
por: Cantini, Fabrizio, et al.
Publicado: (2017)

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact
por: Cantini, Fabrizio, et al.
Publicado: (2020)

Hepatitis C virus infection: a challenge in the complex management of two cases of multidrug-resistant tuberculosis
por: Musso, Maria, et al.
Publicado: (2019)

ASCO update—best of the best
por: Petzer, Andreas
Publicado: (2022)

Antigen discovery by bioinformatics analysis and peptide microarray for the diagnosis of cystic echinococcosis
por: Batisti Biffignandi, Gherard, et al.
Publicado: (2023)

Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy
por: Alonzi, Tonino, et al.
Publicado: (2021)

Best paper and the best reviewer of IJU
por: Kekre, Nitin S.
Publicado: (2010)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_883iplsjcdj21p4ojvi7ecnc0b